LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.35 0.69

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.23

Max

4.39

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+38.34% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

69M

570M

Eelmine avamishind

3.66

Eelmine sulgemishind

4.35

Uudiste sentiment

By Acuity

17%

83%

23 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. veebr 2026, 23:47 UTC

Kuumad aktsiad

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11. veebr 2026, 22:59 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Grab Holdings to Buy U.S.-Based Stash Financial

11. veebr 2026, 23:54 UTC

Tulu

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11. veebr 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11. veebr 2026, 23:49 UTC

Tulu

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11. veebr 2026, 23:45 UTC

Tulu

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11. veebr 2026, 23:42 UTC

Tulu

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11. veebr 2026, 23:41 UTC

Tulu

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11. veebr 2026, 23:40 UTC

Tulu

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11. veebr 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11. veebr 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11. veebr 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11. veebr 2026, 22:58 UTC

Tulu

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11. veebr 2026, 22:57 UTC

Tulu

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11. veebr 2026, 22:54 UTC

Tulu

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11. veebr 2026, 22:53 UTC

Tulu

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:23 UTC

Tulu

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11. veebr 2026, 22:19 UTC

Tulu

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11. veebr 2026, 22:16 UTC

Tulu

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

38.34% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD  38.34%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

23 / 352 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat